Clinical trials
catalyst calendar across sponsors →Studies where NMRA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
7 interventional · 1 with posted results
Held by 11 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, RENAISSANCE TECHNOLOGIES LLC, MARSHALL WACE, LLP, CITADEL ADVISORS LLC, MILLENNIUM MANAGEMENT LLC, +6 more) · FINRA short interest 11.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study to Assess the Safety and Effectiveness of NMRA-335140-501NCT06029439Safety and tolerability assessments based on Treatment Emergent Adverse Events (TEAEs) and validated clinical scalesOpen-label · Treatment | Phase 3 | Active, not recruiting | Drug: NMRA-335140 | Major Depressive Disorder | 1,000 | Jun 2027 | ≤ 314 d | 2026-06-09 |
| Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive DisorderNCT06058013Change from Baseline to Week 6 in the Montgomery-Asberg Depression Rating Scale (MADRS) total scoreRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: NMRA-335140, Placebo | Major Depressive Disorder | 430 | 2026-05-06actual | — | 2026-07-06 |
| Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive DisorderNCT06058039Change from Baseline to Week 6 in the Montgomery-Asberg Depression Rating Scale (MADRS) total scoreRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: NMRA-335140, Placebo | Major Depressive Disorder | 422 | 2026-05-04actual | — | 2026-07-06 |
| Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's DiseaseNCT06546995Part A: Safety and Tolerability Assessments Based on Treatment Emergent Adverse Events (TEAEs) and Validated Clinical ScalesRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: NMRA-323511, Placebo | Alzheimer's Disease, Healthy Elderly | 87 | 2025-11-19actual | — | 2026-05-22 |
| To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.NCT06429722Change from Baseline to Week 6 in the Montgomery-Asberg Depression Rating Scale (MADRS) total scoreRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: NMRA-335140 80 mg, Placebo | Major Depressive Episode Associated With Bipolar II Disorder | 18 | 2025-04-09actual | — | 2026-03-30 |
| Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive DisorderNCT06029426Change from Baseline to Week 6 in the Montgomery Asberg Depression Rating Scale (MADRS) total scoreRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: NMRA-335140, Placebo | Major Depressive Disorder | 383 | 2024-12-03actual | — | 2025-11-26 |
| Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs PlaceboNCT04221230results2025-05-29Change From Baseline in Hamilton Depression Rating Scale (HAMD-17) Total Score at Weeks 8Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: NMRA-335140, Placebo | Major Depressive Disorder | 204 | 2022-04-08actual | — | 2025-05-29 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19